Sensei Biotherapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc. (ticker: SNSE) is a U.S.-listed clinical-stage biotechnology company trading on the Nasdaq market in the United States, with a focus on oncology and next-generation immunotherapy. For French-speaking investors, it should be viewed as an early-stage biotech rather than a commercial pharmaceutical company: the investment case is driven primarily by clinical milestones, pipeline execution, capital needs, and strategic optionality, rather than by recurring product sales. The company was originally incorporated in Maryland in 1999 under the name Panacea Pharmaceuticals, later reincorporated in Delaware in December 2017, and renamed Sensei Biotherapeutics. Its principal executive offices are in Rockville, Maryland, with an additional R&D presence in Boston, Massachusetts. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1829802/000095017025046338/snse-20241231.htm?utm_source=openai)) Sensei was built around a proprietary oncology-immunology platform originally branded ImmunoPhage, aimed at inducing targeted immune responses against cancer. Over time, the company refined its scientific focus toward programs designed to address checkpoint resistance and tumor immune evasion. In 2020, Sensei acquired Alvaxa Biosciences to strengthen its camelid antibody and nanobody engineering capabilities. In 2021, it reprioritized its pipeline around next-generation assets, including SNS-401-NG and SNS-VISTA. The strategic profile changed again in late 2025, when the company announced it would discontinue development of solnerstotug and begin a comprehensive review of strategic alternatives. Then, in February 2026, Sensei announced the acquisition of Faeth Therapeutics and a concurrent $200 million private placement, adding PIKTOR, an oral multi-node inhibitor of the PI3K/AKT/mTOR pathway, with development targeted at solid tumors including endometrial and breast cancer. ([investors.senseibio.com](https://investors.senseibio.com/news-releases/news-release-details/sensei-biotherapeutics-completes-acquisition-alvaxa-biosciences?utm_source=openai)) Operationally, Sensei is still a development-stage company with no mature commercial franchise. Its business lines are concentrated in discovery, preclinical development, and clinical development of cancer therapeutics. That makes its competitive position highly specialized but also highly risky: the company competes in crowded oncology and immuno-oncology fields against larger pharmaceutical groups and better-capitalized biotech peers. Differentiation depends on mechanistic novelty, translational data, and the ability to generate persuasive human clinical evidence. From a geographic standpoint, Sensei’s footprint is essentially U.S.-based, centered in Maryland and Massachusetts, and it does not yet have a meaningful international commercial network. The most important recent corporate events are the strategic shift away from solnerstotug, the acquisition of Faeth, and the new financing that materially reshaped the company’s pipeline and balance-sheet runway. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1829802/000119312526132014/snse-20251231.htm?utm_source=openai))